abstract |
The disclosure provides anti-dengue virus (anti-DENV) antibodies having a cross-reactivity to Zika virus (ZIKV) and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection. In addition, claimed antibodies may further comprise variant Fc regions containing LALA, KAES & ACT5 mutations. |